Clinical Trials in Denver

Showing 8181-8200 of 13,773 trials

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

NCT03035253

The purpose of this study is to test the safety and efficacy of an experimental drug, OMP-305B83, when given in combination with FOLFIRI or FOLFOX. OMP-305B83 is a humanized bispecific monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed that OMP-305B83 may block the growth of cancer stem cells and may also impair the productive growth of new blood vessels, which tumors need to grow and spread. The study is sponsored by OncoMed Pharmaceuticals, which is referred to as OncoMed or the Sponsor.

Metastatic Colorectal Cancer

OncoMed Pharmaceuticals, Inc.16 participantsStarted Dec 2016

Duarte, California, United States • Denver, Colorado, United States • Fort Collins, Colorado, United States +3 more locations

COMPLETEDPhase 2< 1 mile

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

NCT01766817

The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well tolerated in subjects with idiopathic pulmonary fibrosis (IPF).

Idiopathic Pulmonary Fibrosis

Bristol-Myers Squibb325 participantsStarted Jan 2013

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +69 more locations

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

Find Trials by Condition in Denver

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

The Effect of Isotretinoin on the Etonogestrel Contraceptive Implant

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Efficacy and Safety of Intravenous Neridronic Acid in CRPS

Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease

Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma

Dynamic Locking Screws 5.0 vs. Standard Locking Screws in Fracture of Distal Femur Treated With Locked Plate Fixation

Alpha Lipoic Acid in Geographic Atrophy

Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

OIT and Xolair® (Omalizumab) in Cow's Milk Allergy